biobucks - Robuta Search

https://www.fiercebiotech.com/biotech/bristol-myers-hands-over-200m-upfront-1-36b-biobucks-for-agenus-preclinical-tigit-asset Bristol Myers hands over $200M upfront, $1.36B in biobucks for Agenus' preclinical TIGIT asset |... May 18, 2021 - Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact an early-stage assets out of small biotech Agenus. https://www.fiercebiotech.com/biotech/sanofi-shrinks-igm-antibody-partnership-amid-pipeline-reprioritization Sanofi shrinks $6B biobucks deal with IGM Apr 17, 2024 - Sanofi is shrinking a collaboration with IGM Biosciences by half, shedding three cancer targets to focus on three immunology and inflammation targets. sanofi shrinks 6b biobucks deal https://www.fiercebiotech.com/biotech/madrigal-boosts-mash-pipeline-1b-biobucks-license-arrowhead-asset Madrigal boosts MASH pipeline with $1B biobucks Arrowhead deal May 5, 2026 - Madrigal Pharmaceuticals has struck a backloaded deal for the global license to an Arrowhead Pharmaceuticals phase 1 asset for patients with MASH. madrigal boosts mash pipeline 1b https://www.fiercebiotech.com/biotech/bristol-myers-signs-3b-biobucks-deal-century-for-cell-therapies-for-hematologic-solid JPM 2022: Bristol Myers buoys cell therapy interests with $3B biobucks deal with Bayer-backed... Jan 10, 2022 - Is it a once-in-a-century bet? Bristol Myers Squibb will throw in as much as $3 billion for Century Therapeutics' cell therapies and is doling out at least $70... https://www.fiercebiotech.com/biotech/tavros-looks-bullish-despite-bear-market-signs-930m-biobucks-deal-bayers-vividion Bayer's Vividion pens $930M biobucks pact with Tavros Oct 12, 2022 - Though the market is bearish, Tavros is feeling bullish. The biotech signed a pact with Vividion that could garner up to $930 million in biobucks. bayer pens biobucks pact tavros https://www.fiercebiotech.com/biotech/eli-lilly-pens-1-5b-biobucks-pact-china-s-regor-for-metabolic-disease-work Eli Lilly pens $1.5B biobucks pact with China's Regor for metabolic disease work | Fierce Biotech Dec 10, 2021 - Eli Lilly is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to seek out, develop and hopefully sell new therapies for metabolic... https://www.fiercebiotech.com/biotech/anima-eli-lilly-pen-1b-plus-biobucks-research-pact Anima, Eli Lilly pen $1B-plus biobucks research pact | Fierce Biotech Jul 23, 2018 - Little-known private biotech Anima Biotech has signed a deal with Eli Lilly potentially worth more than $1 billion in biobucks as the pair seeks to work on the... eli lilly anima pen 1b https://www.fiercebiotech.com/biotech/sanofi-inks-400m-biobuck-deal-test-mettle-aloys-antisense-platform Sanofi inks $400M biobucks deal for Alloy's antisense platform Jan 8, 2025 - Sanofi is paying $27.5 million in upfront and near-term fees to use an antisense platform in the development of a central nervous system drug. sanofi inks 400m biobucks deal https://www.fiercebiotech.com/biotech/kymera-therapeutics-fresh-off-a-2b-sanofi-biobucks-pact-guns-for-ipo Kymera Therapeutics, fresh off a $2B Sanofi biobucks pact, guns for an IPO | Fierce Biotech Aug 2, 2020 - Preclinical protein degradation biotech Kymera Therapeutics has a great year, nabbing a $102 million round for its march to the clinic, as well as a major tie... https://www.fiercebiotech.com/biotech/takeda-pens-900m-biobucks-pact-carmine-tx-for-non-viral-gene-therapy-work Takeda pens $900M biobucks pact with Carmine for non-viral gene therapy work | Fierce Biotech Jun 30, 2020 - Japanese pharma and biotech friend Takeda is set to spend nearly $1 billion in backloaded payments for a deal with early-stage startup Carmine Therapeutics. https://www.fiercebiotech.com/biotech/novartis-brings-1st-ever-tigit-drug-massive-billion-dollar-biobucks-deal-beigene Novartis brings on first TIGIT drug in massive billion-dollar biobucks deal with BeiGene | Fierce... Dec 20, 2021 - After watching Gilead Sciences and Roche dive deeper into TIGIT immunotherapies, Novartis is heading straight for the senior class.